Use of biomarkers to elucidate genetic susceptibility to cancer

Environmental and Molecular Mutagenesis

Volumn 45, Issue 2-3, 2005, Pages 222-228

  Au, William W ^a   Salama, Salama A ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Biomarkers; Cancer; DNA repair gene polymorphism; Environmental health; Genetic susceptibility

Indexed keywords

AFLATOXIN B1; BENZENE; BENZO[A]PYRENE; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOGEN; CIGARETTE SMOKE; CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; GLYCOPHORIN A; MUTAGENIC AGENT; POLYPHENOL; PROTEIN P53;

CANCER PREVENTION; CANCER SUSCEPTIBILITY; CHROMOSOME ABERRATION; DISEASE ASSOCIATION; DNA DETERMINATION; DNA REPAIR; DNA SEQUENCE; EXCISION REPAIR; GENE MUTATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LUNG CANCER; LUNG LAVAGE; METHYLATION; MOUTH CANCER; PROTEOMICS; REVIEW; SISTER CHROMATID EXCHANGE;

CARCINOGENS, ENVIRONMENTAL; DNA REPAIR; EPIDEMIOLOGY, MOLECULAR; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; NEOPLASMS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; VARIATION (GENETICS);

EID: 17044365040     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/em.20114     Document Type: Review

References (40)

1. Abdel-Rahman S, El-Zein R. 2000. The 399Gln polymorphism in the DNA repair gene XRCCI modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 159:63-71.
2. Au WW. 2001. Life style factors and acquired susceptibility to environmental disease. Int J Hygiene Environ Health 204:17-22.
3. Au WW, Sierra-Torres CH, Tyring SK. 2003a. Acquired and genetic susceptibility to cervical cancer. Mutat Res 544:361-364.
4. Au WW, Salama SA, Sierra-Torres CH. 2003b. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Persp 111:1843-1850.
5. Au WW, Navasumrit P, Ruchirawat M. 2004. Use of biomarkers to characterize functions of polymorphic DNA repair genotypes. Int J Hyg Environ Health 207:301-313.
6. Berwick M, Vineis P. 2000. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 92:874-897.
7. Bonassi S, Abbondandolo A, Camurri L, Dal Prá A, De Ferrari M, Degrassi F, Forni A, Lamberti L, Lando C, Padovani P, Sbrana I, Vecchio D, Puntoni R. 1995. Are chromosome aberrations in circulating lymphocytes predictive of a future cancer onset in humans? preliminary results of an Italian cohort study. Cancer Genet Cytogenet 79:133-135.
8. Bonassi S, Au WW. 2002. Biomarkers in molecular epidemiology studies for health risk prediction. Mutat Res 511:73-86.
9. Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JG. 2003. Increased influence of genetic variation on PON1 activity in neonates. Environ Health Persp 111:1403-1410.
10. Choi JY, Lee KM, Cho SH, Kim SW, Choi HY, Lee SY, Im HJ, Yoon KJ, Choi H, Choi I, Hirvonen A, Hayes RB, Kang D. 2003. CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics 13:349-355.
11. Curtin K, Bigler J, Slattery ML, Caan B, Potter JD, Ulrich CM. 2004. MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. Cancer Epidemiol Biomed Prev 13:285-292.
12. De Roos AJ, Rothman N, Inskip PD, Linet MS, Shapiro WR, Selker RG, Fine HA, Black PM, Pittman GS, Bell DA. 2003. Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors. Cancer Epidemiol Biomed Prev 12:14-22.
13. Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD, Mar EJ, Wain JC, Christiani DC, Kelsey KT. 2000. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21:965-971.
14. Friedberg EC, Walker GC, Siede W. 1995. DNA repair and mutagenesis. Washington, DC: ASM Press.
15. Gao WM, Romkes M, Day RD, Siegfried JM, Luketich JD, Mady HH, Melhem MF, Keohavong P. 2003. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. Carcinogenesis 24:1671-1676.
16. Hagmar L, Brøgger A, Hansteen S, Heim, B, Högstedt B, Knudsen L, Lambert B, Linnainmaa K, Mitelman F, Nordenson I, Reuterwall C, Salomaa S, Skerfving S, Sorsa M. 1994. Cancer risk in humans predicted by increased levels of chromosome aberrations in lymphocytes: Nordic Study Group on the Health Risk of Chromosome Damage. Cancer Res 54:2919-2922.
17. Hagmar L, Stromberg U, Tinnerberg H, Mikoczy Z. 2004. Epidemiological evaluation of cytogenetic biomarkers as potential surrogate end-points for cancer. In: Buffler P, Rice J, Baan R, Bird M, Boffetta P, editors. Mechanisms of carcinogenesis. Lyon: International Agency for Research on Cancer. p 207-215.
18. Harms C, Salama SA, Sierra-Torres C, Cajas-Salazar N, Au WW. 2004. Polymorphisms in DNA repair genes, chromosome aberrations and lung cancer. Environ Mol Mutagen 44:74-82.
19. Hood E. 2003. Proteomics, characterizing the cogs in the machinery of life. Environ Health Persp 111:A817-A826.
20. Hsieh LL, Chien HT, Chen IH, Liao CT, Wang HM, Jung SM, Wang PF, Chang JTC, Chen MC, Cheng AJ. 2003. The XRCC1 399G1n polymorphism and the frequency of p53 mutations in Taiwanese oral squamous cell carcinomas. Cancer Epidemiol Biomed Prev 12:439-443.
21. Hung RJ, Boffeta P, Brennan P, Malaveille C, Gelatti U, Placidi D, Carta A, Hautefeuille A, Porru S. 2004. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis 25:973-997.
22. Lei YC, Hwang SJ, Chang CC, Kuo HW, Luo JC, Chang MJ, Cheng TJ. 2002. Effects on sister chromatid exchange frequency of polymorphisms in DNA repair gene XRCC1 in smokers. Mutat Res 519:93-101.
23. Le Marchand L, Guo C, Benhamou S, Bouchardy C, Cascorbi I, Clapper ML, Garte S, Haugen A, Ingelman-Sunberg M, Kihara M, Rannug A, Ryberg D, Stucker I, Sugimura H, Taioli E. 2003. Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer. Cancer Causes Control 14:339-346.
24. Lohman N, Bladstrom A, Johannsson O, Borg A, Olsson H. 2003. Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Can Res 5:R175-R186.
25. 1-DNA adducts and glycophorin A variant frequency. Cancer Res 59:2557-2561.
26. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, Bell DA. 2000. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21:551-555.
27. Mau L, Hruban R, Boyle JO. 1994. Detection of onocogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 54:1634-1637.
28. Norppa H. 2003. Genetic susceptibility, biomarker response, and cancer. Mutat Res 544:339-348.
29. Qiao Y, Spitz MR. 2002. Modulation of repair of Ultraviolet damage in the host cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 23:295-299.
30. Salama AS, Au WW. 2003. Susceptibility and biomarker knowledge for improvement of environmental health. Int J Hyg Environ Health 206:401-412.
31. Scott FM, Modali R, Lehman TA. 1997. High frequency of K-ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer. Clin Cancer Res 3:479-482.
32. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S, Massa H, Walker M, Chi M, Navin N, Lucito R, Healy J, Hicks J, Ye K, Reiner A, Gilliam TC, Trask B, Patterson N, Zetterberg A, Wigler M. 2004. Large-scale copy number polymorphism in the human genome. Science 305:525-528.
33. Thomas DC, Clayton DG. 2004. Betting odds and genetic associations. J Natl Cancer Inst 96:421-423.
34. To-Figueras J, Gene M, Gomez-Catalan J, Pique E, Borrego N, Caballero M, Cruellas F, Yaya A, Decenta M, Corbella J. 2002. Microsomal epoxide hydrolase and glutathione S-transferase polymorphisms in relation to laryngeal carcinoma risk. Cancer Lett 187:95-101.
35. Virmani AK, Gazdar AF. 2003. Tumor suppressor genes in lung cancer. Methods Mol Biol 222:97-115.
36. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. 2004. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434-442.
37. Waters MD, Selkirk JK, Olden K. 2003a. The impact of new technologies on human population studies. Mutat Res 544:249-360.
38. Waters MD, Olden K, Tennant RW. 2003b. Toxicogenomic approach for assessing toxicant-related disease. Mutat Res 544:415-424.
39. Wikman H, Thiel S, Jager B, Schmezer P, Spiegelhalder B, Edler L, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H, Risch A. 2001. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility, Pharmacogenetics 11:157-68.
40. Xu X, Qiao W, Linke SP, Cao L, Li WM, Furth PA, Harris CC, Deng CX. 2001. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 28:266-271.